Arog Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 20
- Market Cap
- -
- Website
- http://www.arogpharma.com
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02283177
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01657682
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01522469
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Phase 2
Completed
- Conditions
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01243346
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
- First Posted Date
- 2010-10-28
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01229644
- Locations
- 🇺🇸
Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00949624
- Locations
- 🇦🇺
Pfizer Investigational Site, East Melbourne, Victoria, Australia
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Registration Number
- NCT00386555
© Copyright 2024. All Rights Reserved by MedPath